News Releases

Search by year or by keyword :

Date	Title
2022-09-30	Ainos Announces Positive Results from Additional Preclinical Study of Its Low-dose Oral Interferon Formulation Against New Variant Virus – Omicron
2022-08-24	Ainos Submits Investigational New Drug Application to the U.S. FDA to Conduct Phase 2 Trial of its VELDONA Low-dose Oral Interferon Formulation Against Mild COVID-19 Symptoms
2022-08-17	Ainos Announces Master Services Agreement with Swiss Pharmaceutical, Ltd. for Drug Testing, Manufacturing, and Packaging for its VELDONA Product Candidates
2022-08-11	Ainos Announces Closing of $3.3 Million Public Offering, Uplisting to NASDAQ, and Reverse Stock Split
2022-08-08	Ainos Announces Pricing of $3.3 Million Public Offering, Uplisting to NASDAQ, and Reverse Stock Split
2022-06-27	Ainos Announces Positive Results from Preclinical Studies of Its Low-dose Oral Interferon Formulation Against COVID-19
2022-06-21	Ainos COVID-19 Antigen Self-Test Receives Approval for Sale in Taiwan
2021-12-07	Ainos Announces Strategic Relationship with InnoPharmax to Jointly Develop Combined Oral Therapy for Coronavirus Infection
2021-11-03	Ainos SRNA Research Initiative Announces Milestones for mRNA Vaccine Development.
2021-08-16	Ainos Elects Ms. Hui-Lan (Celia) Wu as CFO, Lawrence K. Lin as Executive Vice President of Operations, and Other Key Executives.

United States:

Taiwan: